Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis
Please always quote using this URN: urn:nbn:de:bvb:20-opus-232509
- Purpose Evaluation of long-term outcome and toxicity of moderately hypofractionated radiotherapy using intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost treatment planning and cone beam CT-based image guidance for localized prostate cancer. Methods Between 2005 and 2015, 346 consecutive patients with localized prostate cancer received primary radiotherapy using cone beam CT-based image-guided intensity-modulated radiotherapy (IG-IMRT) and volumetric modulated arc therapy (IG-VMAT) with a simultaneous integratedPurpose Evaluation of long-term outcome and toxicity of moderately hypofractionated radiotherapy using intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost treatment planning and cone beam CT-based image guidance for localized prostate cancer. Methods Between 2005 and 2015, 346 consecutive patients with localized prostate cancer received primary radiotherapy using cone beam CT-based image-guided intensity-modulated radiotherapy (IG-IMRT) and volumetric modulated arc therapy (IG-VMAT) with a simultaneous integrated boost (SIB). Total doses of 73.9 Gy (n = 44) and 76.2 Gy (n = 302) to the high-dose PTV were delivered in 32 and 33 fractions, respectively. The low-dose PTV received a dose (D95) of 60.06 Gy in single doses of 1.82 Gy. The pelvic lymph nodes were treated in 91 high-risk patients to 45.5 Gy (D95). Results Median follow-up was 61.8 months. The 5‑year biochemical relapse-free survival (bRFS) was 85.4% for all patients and 93.3, 87.4, and 79.4% for low-, intermediate-, and high-risk disease, respectively. The 5‑year prostate cancer-specific survival (PSS) was 94.8% for all patients and 98.7, 98.9, 89.3% for low-, intermediate-, and high-risk disease, respectively. The 5‑year and 10-year overall survival rates were 83.8 and 66.3% and the 5‑year and 10-year freedom from distant metastasis rates were 92.2 and 88.0%, respectively. Cumulative 5‑year late GU toxicity and late GI toxicity grade ≥2 was observed in 26.3 and 12.1% of the patients, respectively. Cumulative 5‑year late grade 3 GU/GI toxicity occurred in 4.0/1.2%. Conclusion Moderately hypofractionated radiotherapy using SIB treatment planning and cone beam CT image guidance resulted in high biochemical control and survival with low rates of late toxicity.…
Author: | Jörg Tamihardja, Max Schortmann, Ingulf Lawrenz, Stefan Weick, Klaus Bratengeier, Michael Flentje, Matthias Guckenberger, Bülent Polat |
---|---|
URN: | urn:nbn:de:bvb:20-opus-232509 |
Document Type: | Journal article |
Faculties: | Medizinische Fakultät / Klinik und Poliklinik für Strahlentherapie |
Language: | English |
Parent Title (English): | Strahlentherapie und Onkologie |
ISSN: | 0179-7158 |
Year of Completion: | 2021 |
Volume: | 197 |
Pagenumber: | 124–132 |
Source: | Strahlentherapie und Onkologie (2021) 197:124–132. https://doi.org/10.1007/s00066-020-01678-w |
DOI: | https://doi.org/10.1007/s00066-020-01678-w |
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Tag: | cone beam CT; hypofractionation; image-guided radiation therapy; intensity-modulated radiation therapy; simultaneous integrated boost |
Release Date: | 2021/05/20 |
Licence (German): | CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International |